BCT:CC News and Press, Briacell Therapeutics Corp. From 01/14/26

A look at the top 10 most actives in Canada The Canadian Chrome Company Subordinate Voting Shares (CACR) rose 0.0% to $0.015 on volume of 10,908,480 shares CAT Strategic Metals Corporation (CAT) fell 33.3% to $0.01 on volume of 10,729,757 shares Vanguard Mining Corp. (UUU) fell 17.9% to $0....

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer ca...

[IMAGES BELOW] 11-month sustained complete resolution of lung metastasis observed in Bria-OTS Phase 1/2a metastatic breast cancer study. No treatment limiting toxicities reported. Patient maintained stable disease at all other evaluable sites. PHILADELPHIA and VANCOUVER, British...

How $594B in Precision Tech is Cracking the Metastatic Cancer Code Canada NewsWire Issued on behalf of Oncolytics Biotech Inc.   USANewsGroup.com   News Commentary VANCOUVER, BC , Jan. 7, 2026 /CNW/ -- The global cancer drugs market is surging toward $59...

Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to new treatments for advanced cancers and long COVID BriaCell’s Phase 3 clinical trial in metastatic breast cancer featured as “clinical tria...

BriaCell presents positive clinical data in three posters at the San Antonio Breast Cancer Symposium (SABCS ® ) Phase 3 study of Bria-IMT™ plus immune check point inhibitor (CPI) continues to support biomarkers to identify patients who benefit from treatment with BriaC...

Over 230 patients screened and over 160 patients enrolled in BriaCell’s pivotal Phase 3 study in metastatic breast cancer (MBC) Enrollment exceeding expectations with strong clinical site and patient interest Topline interim data readout expected in 1H2026 ...

Three poster presentations at the San Antonio Breast Cancer Symposium (SABCS), now available and to be presented on December 10, 2025, highlight robust survival and clinical benefit data in Phase 2, plus positive key biomarker data from the pivotal Phase 3 The pivotal Phase 3 study of...

Three poster presentations at the San Antonio Breast Cancer Symposium (December 10, 2025) will highlight positive Phase 2 safety and efficacy signals and positive biomarker findings in both the Phase 2 and the pivotal Phase 3 studies The pivotal Phase 3 study of Bria-IMT+CPI is ongoin...

Collaboration uses Receptor AI's platform to design highly selective anti-cancer kinase inhibitor products for BriaPro, a BriaCell subsidiary Partnership expected to expand BriaPro's small-molecule pipeline Aims to accelerate the development of next generation therapeutics...